Valion Bio, Inc.
VBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeValion Bio, Inc. operates as a late-stage biopharmaceutical company. The company carries a $2.5M market cap, placing it firmly in the micro-cap category. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
Market Cap
$2.5M
Beta
1.79
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-184.45
EPS (Fwd)
—
ROE
-459.5%
ROA
-57.1%
Cash
$2.1M
Total Debt
$17.4M
Free CF
-$8.1M
52W Change
-96.3%
Annual Financials
Cash vs Debt
Where VBIO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VBIO finished 305.19% above its 150-day moving average ($0.77) and 215.15% above its 200-day moving average ($0.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VBIO overbought or oversold?
At the September 3, 2026 close, VBIO's RSI(14) was 85.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $2.1M in cash, though total debt stands at $17.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$8.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -459.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.8M (2022) to $0 (2025), a 100% decline worth watching.
Valion Bio, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VBIO.